Drugs and hepatitis B virus reactivation.
10.7507/1001-5515.202112003
- Author:
Lingyao DU
1
;
Yuanji MA
1
;
Hong TANG
1
Author Information
1. Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, P. R. China.
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Drugs;
Hepatitis B virus;
Immunosuppression;
Reactivation
- MeSH:
Hepatitis B virus;
Humans;
Immunotherapy;
Risk Factors
- From:
Journal of Biomedical Engineering
2022;39(3):627-632
- CountryChina
- Language:Chinese
-
Abstract:
Drugs may induce hepatitis B virus (HBV) reactivation (HBV-R). Here we have reviewed the definition and harm of HBV-R, the risk drugs and their underlying mechanism, the influence factors, as well as the early intervention measures. It is shown that multiple drugs, including chemotherapy drugs, immunotherapy drugs, directly acting antivirals, cell therapy, etc., can induce HBV-R by affecting host immunity or directly activating HBV transcription factors. HBV-R could cause severe liver damage, even interruption of treatment of original diseases, affecting the prognosis of patients. Through precisely identifying risk drugs, monitoring the influence factors, and prescribing preventive anti-HBV regimen if necessary, the incidence of HBV-R can be significantly reduced. It is also suggested that clinical physicians should not only pay attention to the early identification and intervention of HBV-R, but also further study the mechanism of HBV-R in depth, especially the underlying mechanism between host, HBV and risk factors. This will help to promote the discovery of more valuable markers for risk prediction and targets for early intervention, and to further reduce the risk of HBV-R and improve the prognosis of patients.
